Synthetic healthcare data is moving from “nice-to-have” to a practical default for dev/test and data sharing—especially where PHI constraints slow delivery. One vendor guide highlights concrete time savings in testing and a public-health pattern for publishing usable datasets without exposing individuals.
Tonic spotlights synthetic data for HIPAA-safe dev/test and research sharing
Tonic published a guide arguing that synthetic healthcare data—generated to mirror real patient data without using actual health records—can help healthcare organizations improve privacy posture while speeding software development. The piece frames synthetic data as a way to reduce exposure to protected health information (PHI) while still enabling realistic application testing and analytics under regulations such as HIPAA.
On the delivery side, the guide notes that software testing can take 30–40% of overall development time, and claims synthetic data can reduce bottlenecks caused by limited access to high-quality test datasets. As an example, it cites Patterson Dental reducing test-data generation time from 2.5 hours to 35 minutes, enabling more extensive performance testing and more daily test runs. On the research/public-use side, it points to the CDC’s National Center for Health Statistics using synthetic data generation to create public-use datasets from sensitive mortality files, aiming to preserve high statistical accuracy while protecting individual privacy.
- Dev/test velocity without PHI sprawl: If teams can generate realistic datasets on demand, they can decouple testing pipelines from production extracts—reducing the need for repeated approvals, refresh cycles, and PHI handling in lower environments.
- Compliance burden shifts from access control to quality controls: Synthetic data doesn’t eliminate governance work; it changes it. Expect more emphasis on utility validation, privacy risk assessment, and documenting generation methods for auditors and internal risk teams.
- Better “shareability” for research and partners: The CDC NCHS example reflects a broader pattern: synthetic public-use datasets can expand who can analyze sensitive domains (mortality, outcomes, utilization) without distributing raw records.
- Procurement questions get sharper: The Patterson Dental time reduction is the kind of metric buyers will demand. Data leads should ask vendors what drives the delta (schema complexity, constraints, refresh cadence) and how performance/utility was measured.